How Novartis and Boehringer Are Slashing Prices

Novartis and Boehringer Ingelheim are making waves with new direct-to-patient programs that promise much lower prices for some of their most visible drugs in the U.S. These moves follow recent pressure from the government and growing demand for affordability.

Beginning November 1, Novartis will launch a program that allows cash-pay patients prescribed Cosentyx to buy it directly at about 55 percent off the list price. With the current wholesale cost of Cosentyx for self-injectable immunology treatments nearly eight thousand dollars per month, that discount brings the price down to roughly thirty-five hundred for eligible patients paying out of pocket. Novartis says the price cut mirrors what insurers and pharmacy benefit managers typically pay. The company views this first move as proof of concept for a model that could reshape how patients access specialty medicines.

Boehringer’s program takes a broader approach. Its “Access” platform offers home delivery of Spiriva Respimat, an inhaler for asthma and COPD, at a dramatically reduced cost. For those paying out of pocket the monthly price is about thirty-five dollars compared with more than six hundred at list price. Patients using insurance, flexible spending accounts or other affordability tools will see savings also, with shipping included. Boehringer plans to roll more of its respiratory inhalers and its diabetes medicines into this platform in coming months.

What is especially noteworthy is how both companies are embracing direct sale or direct delivery models as a response to mounting criticism that drug prices are opaque and unfair. For patients who pay cash, the programs offer a clearer, cheaper path. For others, the affordability tools built into the platforms may help reduce financial burden.

There are still questions. Eligibility for these programs, how “list price” is defined, and whether these discounts will persist over time remain to be seen. For patients relying on insurance, the impact could vary depending on coverage and deductibles. And while these programs address cash-pay patients, many rely on insurance or other payment mechanisms.

These developments matter because they signal a shift. When major pharma players begin offering big discounts directly to patients, they acknowledge that traditional pricing systems and intermediaries may be failing many people. Whether this marks a sustained change or a temporary response to pressure will depend on how the industry, regulators and payers react.

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com